Comparison of tumour necrosis factor and endothelin-1 between essential and renal hypertensive patients

Journal of Human Hypertension

Volumn 12, Issue 6, 1998, Pages 351-354

  Cottone, S ^a,b   Vadala A ^a   Vella, M C ^a   Mule G ^a   Contorno, A ^a   Cerasola, G ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b NONE   (Italy)

Author keywords

Arterial hypertension; Endothelial dysfunction; Endothelin; Tumour necrosis factor

Indexed keywords

ALBUMIN; CREATININE; ENDOTHELIN 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MALE; MEAN ARTERIAL PRESSURE; NORMAL HUMAN; RENOVASCULAR HYPERTENSION; SYSTOLIC BLOOD PRESSURE; URINE LEVEL;

EID: 0031852020     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000596     Document Type: Article

References (31)

1. Sedor JR. Cytokines and growth factors in renal injury. Semin Nephrol 1992; 12: 428-440.
2. Diez J et al. Insulin-like growth factor binding proteins in arterial hypertension: relationship to left ventricular hypertrophy. J Hypertens 1995; 13: 349-355.
3. Lindop GBM, Boyle JJ, McEwan P, Kenyon CJ. Vascular structure, smooth muscle cell phenotype and growth in hypertension. J Hum Hypertens 1995; 9: 475-478.
4. Atkins RC, Kerr PG. Cellular immunity in renal disease. In: Massry SG, Glassock RJ (Eds). Textbook of nephrology. Williams & Wilkins: London, 1995, pp 643-647.
5. Baud L, Ardaillaou R. Tumor necrosis factor alpha in glomerular injury. Kidney Int 1994; 45 (Suppl 45): S32-S36.
6. Tipping PG, Leong TW, Holdsworth SR. Tumor necrosis factor production by glomerular macrophages in anti-glomerular basement membrane glomerulonephritis in rabbit. Lab Invest 1991; 65: 272-279.
7. Mulligan MS et al. Requirements for leukocyte adhesion molecules in nephrocytic nephritis. J Clin Invest 1993; 91: 577-587.
8. Packer M. Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure. Circulation 1995; 92: 1379-1382.
9. Lianos EA. Role of cytokines, eicosanoids, and growth factors in glomerular and vascular injury. In: Massry SG, Glassock RJ (Eds). Textbook of nephrology. Williams & Wilkins: London, 1995, pp 652-659.
10. Webb DJ. Endogenous endothelin generation maintains vascular tone in humans. J Hum Hypertens 1995; 9: 459-463.
11. Kon V et al. Role of endothelin in cyclosporineinduced glomerular dysfunction. Kidney Int 1990; 37: 1487-1491.
12. Yamada K, Yoshida S. Role of endogenous endothelin on renal function in rats. Am J Physiol 1991; 260: F34-F38.
13. Takahashi K, Totsune K, Mouri T. Endothelin in chronic renal failure. Nephron 1994; 66: 373-379.
14. Brown M, Chou SY, Porush JG. Endothelins and kidney diseases. Nephron 1996; 72: 375-382.
15. Cottone S et al. Changes of plasma endothelin and growth factors levels, and of left ventricular mass after chronic AT1 receptors blockade in human hypertension. Am J Hypertens (in press).
16. Marsden PA, Brenner BM. Transcriptional regulation of the endothelin-1 gene by TNF-alfa. Am J Physiol 1992; 262: C854-C861.
17. Baud L, Perez J, Friedlander G, Ardaillaou R. Tumor necrosis factor stimulates prostaglandin production and cyclic AMP levels in rat cultured mesangial cells. FEBS Lett 1988; 239: 50-54.
18. Floege J et al. Monokines and platelet derived growth factor modulate prostanoid production in growtharrested human mesangial cells. Kidney Int 1990; 37: 859-869.
19. de Kossodo S et al. WHO Collaborative Study Group: assaying tumor necrosis factor concentrations in human serum. A WHO International Collaborative Study. J Immunol Methods 1995; 182: 107-114.
20. Mulvany MJ. Resistance vessel growth and remodelling: cause or consequence in cardiovascular disease. J Hum Hypertens 1995; 9: 479-485.
21. Cottone S, Cerasola G. Microalbuminuria fractional clearance and early renal permselectivity changes in essential hypertension. Am J Nephrol 1992; 12(5): 326-331.
22. Diez J, Laviades C, Mayor G. Effects of anti-hypertensive therapy on left ventricular hypertrophy of essential hypertension: a role for insulin-like factor I? J Hum Hypertens 1993; 7: 479-484.
23. Naftilan AJ, Pratt RE, Dzau VJ. Induction of plateletderived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83: 1419-1424.
24. Gibbons JH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs hyperplasia: autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest 1992; 90: 456-461.
25. Floege J et al. Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney Int 1992; 41: 297-309.
26. Pedrinelli R et al. Albuminuria and endothelial dysfunction in hypertensive atherosclerotic patients. Clinical Hypertension in Nephrology, Vibo Valentia (Italy), Abstract book p 35 (Abstract), September 1995.
27. Liu I et al. Quantitation of perivascular monocytes and macrophages around cerebral blood vessels in hypertensive and aged rats. J Cereb Blood Flow Metab 1994; 14: 348-352.
28. Liu I et al. Evidence for activation of endothelium and monocytes in hypertensive rats. Am J Physiol 1996; 270: H2125-H2131.
29. Davemport AP et al. A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma: comparison of levels in patients with essential hypertension and normotensive controls. Clin Sci 1990; 78: 261-264.
30. Ergul S et al. Racial differences in plasma endothelin1 concentrations in individuals with essential hypertension. Hypertension 1996; 28: 652-655.
31. Cerasola G et al. Microalbuminuria, renal dysfunction and cardiovascular complication in essential hypertension. J Hypertens 1996; 14: 915-920.